>I would suggest that the FDA is much more likely to approve based upon scientific merits.<
The good news is that no fault has been found with GTC’s science. No one—not even the EMEA—is saying that ATryn is inferior to plasma-derived antithrombin. Hence eventual approval in some jurisdiction still seems likely. The question, of course, is whether GTC will be around when that happens.
Market Data 
Markets 
AI
